Valued at $50 billion, the Indian pharmaceutical sector continues to grow, fueled by cost efficiency, cutting-edge ...

The Institute for Clinical and Economic Review has prepared a special report on Trelegy and Breo, two therapies that treat ...

A Tebra survey found that 84% of Americans believe generic medications are just as effective as their brand-name counterparts ...

Ever bought a pair of ‘abibas’ slides from Pettah? Or some ‘Colvin Klean’ underwear? No harm if you have (reputational harm ...

JP Morgan upgrades Amneal Pharmaceuticals, citing strong Crexont sales, robust generics growth, and a higher 2025 revenue ...

The differences between the generics industry and other pharma companies wouldn’t exist without patents – legal titles that exclude others from producing or using an invention or innovation ...

Industry leaders warn that potential US tariffs on Indian pharmaceutical exports could increase drug costs for American ...

arguing that four out of 10 products covered by the scheme are actually branded generics or biosimilars, but was prevented from doing so by a High Court ruling. Samuels said today that the BGMA ...

ANI Pharmaceuticals offers an asymmetric opportunity in small-cap pharma, with a niche in generics, rare disease treatments, and contract manufacturing. Despite cash burn concerns, ANI's revenue ...

ANI Pharmaceuticals beat Q4 estimates with strong sales growth and raised its 2025 revenue and EPS outlook, driven by ...

The Ireland-headquartered Felix Pharmaceuticals, which is eyeing a valuation of around $200-250 million for the controlling ...